Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...

LTC pharmacists could counter those losses because they delivered so many of the high-priced name-brand drugs such as the blood thinners Eliquis and Xarelto or Farxiga or Januvia for diabetes.

If you're not happy with the results, please do another search.

Changing diabetes medications isn't something you ... liver toxicity DPP-4 inhibitors Januvia (sitagliptin) and Tradjenta ...

Sitagliptin (Januvia; Merck), the only marketed DPP4 ... With 394 candidates in development in 2006, (344 in 2005), diabetes is second only to cancer in R&D focus 3. This is not surprising given ...

Merck already has the world’s biggest selling oral treatment for type 2 diabetes, its DPP-4-based drugs Januvia and Janumet, but it is playing catch-up in the SGLT2 market. The monotherapy and ...

On a downbeat note, sales of its diabetes drugs Januvia and Janumet have lagged, although sales of its other drugs have picked up the slack, with Roche reporting Q4 revenues up 7% on an annual basis.

Is Victoza similar to Januvia or Jardiance? Yes, in some ways. Victoza is used in people with type 2 diabetes to help manage blood sugar levels. It’s also used to lower the risk of severe heart ...

Metabolic diseases is already a focus area for Merck & Co – it markets several diabetes drugs including Januvia (sitagliptin) and last year exercised an option to develop NGM313, an antibody ...

All the latest breaking news on United States. Browse ibtimes archives of photos, videos and articles on United States.